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In November 2014 the National Institute for Health and Care Excellence (NICE) issued 
recommendations for the use of high-sensitivity cardiac troponin (hs-cTn) assays in the United 
Kingdom [1].  Two assays were evaluated: the Elecsys hs-cTnT assay (Roche Diagnostics) and the 
ARCHITECT hs-cTnI assay (Abbott Laboratories). On the basis of both clinical and economic evidence, 
NICE recommended that hs-ĐdŶĂƐƐĂǇƐĐŽƵůĚďĞƵƐĞĚƚŽ ?ƌƵůĞŽƵƚ ?ƚŚĞĚŝĂŐŶŽƐŝƐŽĨ ŶŽŶ-ST elevation 
myocardial infarction (NSTEMI) within 4 hours of patients arriving in an Emergency Department (ED).  
E/ĨƵƌƚŚĞƌƐƚĂƚĞĚƚŚĂƚƚŚŝƐǁŽƵůĚƚǇƉŝĐĂůůǇŝŶǀŽůǀĞ ?ƌƵůŝŶŐŽƵƚ ?E^dD/in patients with hs-cTn 
concentrations below the 99
th
 percentile upper reference limit when tested both on arrival in the ED 
and three hours later.  This recommendation was based on the findings of a commissioned 
systematic review [2].  The systematic review had pooled existing evidence from 18 studies to define 
ŵŽƌĞŐƌĂŶƵůĂƌ ?ŽƉƚŝŵĂů ?ƚĞƐƚŝŶŐƐƚƌĂƚĞŐŝĞƐĨŽƌĞĂĐŚŚƐ-cTn assay. However, diagnostic strategies 
based on such models may not perform as well when used in practice. In this issue of the Journal, 
two studies have made efficient use of existing data from large cohort studies to further evaluate 
the accuracy of those diagnostic strategies [3,4]. 
 
Pickering et al pooled data from five cohort studies to examine the diagnostic accuracy of hs-cTn 
measured on arrival and 3 hours later, using standard cardiac troponin testing as the reference 
standard [3].  Four of the five studies included had set out to evaluate hs-cTn measurement 2 hours 
after arrival. However, in practice a significant proportion of participants underwent hs-cTn testing 
between 3 and 4.5 hours after arrival and this group was included in the current analysis.  The 
findings may come as a surprise.  Using the 99
th
 percentile cut-off, this 3-hour rule out strategy had a 
sensitivity of just 93.2% (95% CI 87.5  ? 96.8%) with hs-cTnI and 94.8% (95% CI 89.6  ? 97.9%) with hs-
cTnT.  The number of patients in each of the five individual cohorts was too small to allow 
meaningful direct comparisons that could help us to understand whether this may be partly 
explained by different assays used as a reference standard or by differences in the proportion of 
patients presenting within a few hours of symptom onset.  
 
Pickering et al conclude that pathways based exclusively on the 99
th
 percentile should not be used to 
rule out NSTEMI in clinical practice and propose an alternative that combines a low threshold for risk 
stratification at presentation [5,6] and delta criteria to identify patients with rising cardiac troponin 
concentrations at 3 hours that remain below the 99
th
 percentile. This approach would improve the 
sensitivity from 93.7% to 99.2% (1 false negative) for hs-cTnI and from 94.8% to 99.3% (1 false 
negative) for hs-cTnT. The pathway requires external validation, but the concept of harnessing the 
additional sensitivity these assays give in patients with troponin concentrations within the normal 
reference range is important. This approach will help risk stratify patients and identify the small 
number of patients who will continue to require testing at 6 hours, and will help to improve the 
safety and efficacy of early rule out pathways.   
 
Parsonage et al also pooled data from three existing datasets to evaluate the optimal testing 
strategies for ruling out NSTEMI defined in the NICE systematic review [4]. This post-hoc analysis of 
observational data evaluated performance of the  ?ŽƉƚŝŵĂů ?ƚĞƐƚŝŶŐƐƚƌĂƚĞŐŝĞƐ used to model the 
clinical and cost-effectiveness of the hs-cTnI and hs-cTnT assays in the NICE technology appraisal. 
They observed that the hs-cTnI testing strategy had a higher false negative rate than the model 
(2.0% versus 0.4%), and the hs-cTnT pathway ruled out a smaller proportion of patients than 
anticipated by the model (53% versus 69%). There are some limitations that arise in pooling data 
from different cohorts. First, the diagnostic endpoint of acute myocardial infarction was adjudicated 
using a variety of assays. Whilst the hs-cTnI pathway ruled out the expected proportion of patients 
(80% versus 78%) the sensitivity was low at 89%. The majority of false negatives (37/51) were from 
the cohort of patients where a hs-cTnT assay was used to adjudicate the final diagnosis. It is likely 
that the observed performance of the hs-cTnI assay at presentation and 3 hours would have been 
better if the index diagnosis was based on serial sampling over 6 hours with the same assay. Second, 
in two of the three cohorts included in this analysis the second blood sample was drawn after 2 
hours (rather than 3 hours, as specified in the NICE recommendations). It is possible that this earlier 
sampling time may have reduced the observed sensitivity and negative predictive value. 
 
However, based on their findings, Parsonage et al recommend that neither of the testing strategies 
using hs-cTnI and hs-cTnT should be used to rule out NSTEMI in clinical practice. This raises the 
question of what strategy should be used. The NICE review was a technology appraisal rather than a 
clinical guideline and, as such, recommended the general principle of using hs-cTn in an early rule 
out protocol rather than a specific pathway. It was based on an economic analysis showing that early 
rule out protocols are cost-effective compared to a standard cTn assay at 10-12 hours. Since delayed 
testing is more expensive than early testing the economic analysis may be best understood as 
showing that the additional cases detected by delayed testing do not justify the additional costs, as a 
general principle. The specific choice of which early rule out pathway to use depends upon clinical 
interpretation of the accuracy data.  Systematic appraisal and the development of innovative testing 
strategies like those reported in this edition of the journal will help clinicians to maximise the 
potential of high-sensitivity cardiac troponins and improve the safety and effectiveness of our 
Emergency Departments.  
 
The findings of these two papers should not lead us to conclude that the NICE recommendations, 
which focus on guiding the cost-effective use of NHS resources, are inappropriate. However, they do 
suggest that diagnostic accuracy may be lower than originally anticipated. This serves to emphasise 
the potential tension between cost-effectiveness and the clinical safety of rule out algorithms. It also 
highlights the need for future work to externally validate these findings, and to determine whether 
additional clinical risk stratification (which was outside the scope of the NICE recommendations) will 
optimise the safety and effectiveness of the rule out strategies that NICE and the European Society 
of Cardiology currently recommend.  
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